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Background: To assess the safety and efficacy of simultaneous integrated boost (SIB) or late course accelerated
boost (LCAB) with external beam radiotherapy (EBRT) to the vaginal cuff for high risk cervical cancer patients after
radical hysterectomy.
Methods: Between October 2009 and January 2012, patients with high risk cervical cancer who had undergone
radical surgery followed by EBRT to the vaginal cuff were enrolled. Patients were treated with either intensity
modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) with SIB (arm A) or IMRT/VMAT to the
pelvis followed by LCAB (arm B) to vaginal cuff. In arm A, the pelvic and boost doses were 50.4 Gy and 60.2 Gy in
28 fractions, respectively. In arm B, pelvic irradiation to 50 Gy in 25 fractions followed by a boost of 9 Gy in 3
fractions were delivered. Chemotherapy was given concurrently.
Results: Overall, 80 patients were analyzed in this study (42 in arm A, 38 in arm B). In arm A and B, median follow-up
was 37 and 32 months, respectively. The 3-year disease-free survival and overall survival in arms A vs B were 88.7% vs.
93.4% (p = 0.89), and 91.8% vs.100% (p = 0.21), respectively. The 3-year local-regional control and distant failure were
97.6% vs. 100% (p = 0.34), and 4.8% vs. 5.3% (p = 0.92), respectively. Grade 3–4 acute leukopenia and dermatitis were
seen in 11 (26.2%) and 8 (19.0%) patients in Arm A, vs. 7 (17.8%) and 6 (15.8%) patients in Arm B, respectively (p > 0.05).
Only Grade 1–2 chronic gastrointestinal (GI) and genitourinary (GU) toxicities were observed.
Conclusions: Our results indicate that both SIB and LCAB to vaginal cuff for high risk cervical cancer patients after
radical hysterectomy are associated with excellent survival, local control and low toxicity.
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Cervical cancer constitutes the leading cause of cancer
death among women in developing countries [1,2]. In
early stage cervical cancer, surgery remains a major step
of the therapeutic treatment. However, in women who
are considered to be at high risk for recurrence due to
additional risk factors, adjuvant radiotherapy following
radical hysterectomy has been recommended [3-5].
Postoperative adjuvant radiotherapy for cervical cancer
includes external beam radiation therapy (EBRT) and va-
ginal brachytherapy. Although there is no clear agreement
as to the indications for performing vaginal brachytherapy
after radical hysterectomy for cervical cancer, it is typically
employed as a boost after EBRT [6]. The current National
Comprehensive Cancer Network (NCCN) cervical cancer
guidelines [7] and American Brachytherapy Society con-
sensus guidelines both suggest that brachytherapy may be
used as a boost to EBRT in postoperative patients with
high risk factors, such as close or positive margins, a less
than radical hysterectomy, large or deeply invasive tumors,
extensive lymphovascular invasion, or parametrial or vagi-
nal involvement [6]. However, in certain circumstances,
vaginal brachytherapy may not be feasible due to patient
refusal to undergo the procedure, unfavorable anatomy,
coexisting medical conditions, or the lack of availability of
brachytherapy in the institution. For these patients, EBRT
can offer an alternative form of treatment. At the same
time, with the rapid development of recent EBRT tech-
niques, such as intensity-modulated radiotherapy (IMRT),
volumetric-modulated arc therapy (VMAT), three dimen-
sional- conformal radiotherapy (3D-CRT) andstereotactic
radiotherapy, a radiation boost to the vaginal cuff and
parametria can be achieved. Some studies explored these
EBRT boost methods in patients with locally advanced
cervical or endometrial cancer, and reported that deliver-
ing a total dose of 54–81.2 Gy was well tolerated and effi-
cacious [8-12].
To patients after radical hysterectomy, the total EBRT
boost dose prescribed to the vaginal cuff is lower than
that employed in patients with unresected disease or
gross residual tumor following a hysterectomy. As such,
it may be reasonable and feasible to use EBRT to boost
the vaginal cuff in high risk patients following a radical
hysterectomy. This may be accomplished with a number
of EBRT techniques, including IMRT, VMAT and 3D-
CRT; it may also be delivered simultaneously or sequen-
tially with whole-pelvic irradiation.
The purpose of this study is to report a single-
institution experience using adjuvant EBRT to boost the
vaginal cuff in high risk cervical cancer patients after
radical hysterectomy, and compare two techniques for
doing so, simultaneous integrated boost (SIB) with IMRT/
VMAT and late course accelerated boost (LCAB) follow-
ing pelvic IMRT/VMAT. To our knowledge, this is thefirst EBRT boost study in postoperative cervical cancer pa-
tients with high risk.
Methods
Patients
Patients treated at a single institution between October
and January 2012 were evaluated if they underwent a
radical hysterectomy with pelvic lymphadenectomy fol-
lowed by adjuvant pelvic EBRT with EBRT vaginal cuff
boost for a clinical stage IB-IIA cervical cancer, or for a
stage IIB cervical cancer following neoadjuvant chemo-
therapy, but did not achieve a complete pathological re-
sponse to neoadjuvant treatment. Patients were eligible
for analysis if they had at least one of the following high
risk factors after resection: close margins, large tumors
(>4 cm), deep stromal invasion (defined as invasion into
the deeper half of the cervical wall), extensive lympho-
vascular invasion, positive pelvic lymph nodes, or para-
metrial involvement. In addition, patients were required
to have an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1, a histologically negative sur-
gical margin, and radiographically negative para-aortic
lymph nodes. The EBRT boost to vaginal cuff was deliv-
ered as either IMRT/VMAT SIB (arm A) or IMRT/VMAT
to the pelvis followed by LCAB with 3D-CRT (arm B) at
the Department of Abdominal Oncology of West China
Hospital of Sichuan University. The treatment protocols
(arm A and arm B) were determined by the treating physi-
cians. All patients were staged according to International
Federation of Gynecology and Obstetrics (FIGO) protocol.
The study was approved by the West China Hospital insti-
tutional review board. All patients provided written in-
formed consent.
Radiation therapy
All patients were immobilized in the supine position with
abdominal body thermoplastic masks, and underwent hel-
ical computed tomography (CT, Siemens Sensation 4) at
3 mm slice thickness with intravenous contrast. All plan-
ning was performed using the Pinnacle treatment plan-
ning system (TPS). The clinical target volume (CTV) and
organs at risk (OARs) (i.e., bladder, rectum, small bowel
and femoral head) were contoured on sequential axial CT
slices. CTV1 included the proximal two-thirds of the va-
gina, paravaginal soft tissue lateral to the vagina and pelvic
lymph nodes (common, internal and external iliac, and
presacral lymph node regions), and delineated according
to the consensus guidelines for the delineation of the
CTV in postoperative pelvic radiotherapy of endometrial
and cervical cancer [13]. CTV2 included the proximal
two-thirds of the vagina and paravaginal soft tissue lateral
to the vagina. In order to decrease CTV geometric uncer-
tainty, patients received instruction in bladder and rectum
control. Patients were instructed to empty their bladder
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tion and each treatment, with the intention of having a
moderately-full and comfortable bladder. Patients were
also encouraged to move their bowels and to have an
empty rectum in advance of their daily treatments. The
planning target volumes (PTV1 and PTV2) were created
by extending CTV1 and CTV2, respectively, using a mar-
gin of 10 mm in the axial plane except anterior to the rec-
tum, where the margin was 5 mm. Extended treatment
fields were not used. The rectum was contoured from the
anus to the rectosigmoid flexure. The bladder was con-
toured as a \solid organ. In order to account for the dis-
placement of the small bowel, the entire peritoneal cavity
was contoured up to 1 cm above the superior extent of
the PTV.
In arm A, 50.4 Gy/28 fractions and 60.2 Gy/28 frac-
tions were delivered to PTV1 and PTV2, respectively,
with an IMRT/VMAT SIB technique. In arm B, a dose
of 50 Gy/25 fractions was delivered to PTV1 with an
IMRT/VMAT technique, followed by a boost of 9 Gy/3
fractions delivered to PTV2 with 3D-CRT. All radiother-
apy was delivered with 6 MV photons daily, 5 days per
week. Inversely-planned step-and-shoot IMRT, VMAT
and 3D-CRT plans generated. Cumulative dose-volume
histograms were reviewed. Plans were acceptable if the
prescribed dose covered >95% of the PTV and no more
than 1 cc received >107% of the prescribed dose. Typical
normal tissue constraints were as follows: <50% bladder
was to receive 50 Gy, <50% rectum was to receive
50 Gy, <40% of small bowel was to receive 40 Gy, and
<5% of the femoral heads were to receive 50 Gy.
Adjuvant radiotherapy began within 3 months after sur-
gery. All patients received 4 cycles of adjuvant chemother-
apy concurrently with their radiotherapy, using either
paclitaxel & cisplatin (TP), 5-FU & cisplatin (FP) or bleo-
mycin & cisplatin (BP). Patients with stage IIB disease had
neoadjuvant chemotherapy to down-stage the tumor.
Follow-up
Adverse events (AEs) were assessed on a weekly basis dur-
ing treatment using the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events, version 3.0
(CTCAE v 3.0). After treatment, patients were followed
up every 3 months for 2 years, then every 6 months for
the following 3 years. Follow-up assessments were based
on either physical examination by the radiation oncolo-
gists or CT scans.
Statistics
We estimated local-regional control (LC), distant failure
(DF), and AEs using cumulative incidence functions.
Disease-free survival (DFS) and overall survival (OS)
were estimated using the Kaplan-Meier method; com-
parisons between groups were made using the log-ranktest. DFS was defined as the time between hysterectomy
and first evidence of disease recurrence or the most re-
cent follow-up. OS was defined as the time between hys-
terectomy and death from any cause or the most recent
follow-up. For the purposes of DFS, patients were cen-
sored at the time of last follow-up or death without any
progression of disease. For the purposes of OS, patients
were censored at the time of last follow-up. Differences
between the two arms were evaluated using a two-sample
t-test for continuous variables and Pearson’s chi-square
test was used for categorical data. Statistical analysis was
conducted using PASW Statistics (SPSS, IBM Corpor-
ation). For all analyses, a P value of <0.05 was considered




Overall, a total of 80 patients were analyzed in this study
(42 in arm A, 38 in arm B). Patient characteristic data are
summarized in Table 1. The median follow- up interval
was 37 months (range, 15–49) in arm A and 32 months
(range, 16–47) in arm B. The median age was 45 (range,
33–57 years) and 44 (range, 33–69) years in arms A and
B, respectively. There were no significant differences be-
tween the baseline patient characteristics of the two arms
(p > 0.05) (Table 1).
The treatment characteristics are summarized in Table 2.
There were 11 and 12 patients treated with VMAT, as well
as 31 and 26 patients treated with IMRT in arms A and B,
respectively. Image-guided radiotherapy was used in 8 and
12 cases in arms A and B, respectively (Table 2). 36 pa-
tients in arm A and 34 patients in arm B were also treated
with chemotherapy. 16 and 19 patients with stage II in
arm A and B underwent neoadjuvant chemotherapy, re-
spectively (Table 2). All of these patients achieved tumor
shrinkage and then received radical hysterectomy with
pelvic lymphadenectomy.
The biological equivalent dose (BED) to the vaginal
cuff was calculated with the linear-quadratic model to be
73.14 Gy in arm A and 71.7 Gy in arm B, assuming a
2 Gy/fraction schedule, with α/β = 10. Concurrent che-
moradiotherapy was well tolerated, with only 4 (9.5%)
and 3 (7.9%) of treatment interruptions in arms A and
B, respectively.
Outcomes
In this study, local failure alone occurred in 1 patient in
arm A, who had an isolated vaginal cuff recurrence,
while there was no local-regional recurrence observed in
arm B. The 3-year LC rates were 97.6% for arm A and
100% for arm B (p = 0.34). Distant metastasis occurred
in 2 patients in each arm. In arm A, the sites of distant
metastasis were retroperitoneal nodes and supraclavicular






N (%) N (%)
Radiotherapy 0.60
VMAT 11 (26.2) 12 (31.6)
IMRT 31 (73.8) 26 (68.4)
IGRT 8 (19.0) 12 (31.6) 0.19
Chemotherapy Regimen 0.78
TP 15 (35.7) 14 (36.8)
BP 13 (31.0) 15 (39.5)
FP 8 (19.0) 5 (13.2)
No Chemotherapy 6 (14.3) 4 (10.5)
Neoadjuvant Chemotherapy 16 (38.1) 19 (50.0) 0.28
VMAT: volumetric modulated arc therapy; IMRT: intensity modulated
radiotherapy; IGRT: Image-guided radiation therapy; TP: paclitaxel & cisplatin;
BP: bleomycin & cisplatin; FP: 5-FU & cisplatin.










n (%) n (%)
FIGO stage 0.71
IB 12 (28.6) 9 (23.7)
IIA 15 (35.7) 12 (31.6)
IIB 15 (35.7) 17 (44.7)
Histology 0.40




G1: Well differentiated 3 (7.1) 1 (2.6)
G2: Moderately differentiated 7 (16.7) 6 (15.6)
G3: Poorly differentiated 32 (76.2) 31 (81.6)
Lymph node metastases 0.59
+ 12 (28.6) 13 (34.2)
- 30 (71.4) 25 (65.8)
CLS 0.89
+ 15 (35.7) 13 (34.2)
- 27 (64.3) 25 (65.8)
Stromal invasion 0.15
Superficial half 6 (14.3) 3 (7.8)
Deep half 22 (52.4) 28 (73.7)
Whole stroma 14 (33.3) 7 (18.4)
CLS: capillary lymphatic space.
Wang et al. BMC Cancer  (2015) 15:257 Page 4 of 8nodes, while in arm B, the lung and liver were involved.
The 3-year DF were 4.8% for arm A and 5.3% for arm B
(p = 0.92). Figure 1 shows the DFS of two arms. The 1, 2,
3-year DFS for arms A and B were 97.1% vs. 96.8%, 93.9%
vs. 93.4%, and 88.7% vs. 93.4%, respectively. There was no
significant difference between two groups (p = 0.89). Dur-
ing follow-up, there was only 1 patient death, in arm A.
The 3-year OS for arm A and B were 91.8% and 100%, re-
spectively (p = 0.21) (Figure 2).
Adverse events
Acute treatment-related Grade 3–4 AEs during treat-
ment were shown in Table 3. Leukopenia was the most
common Grade 3–4 acute AEs, and was seen in 11
(26.2%) and 7 (17.8%) patients in Arm A and B, respect-
ively (Table 2). Grade 3 dermatitis was seen in 8 (19.0%)
and 6 (15.8%) patients in two arms, respectively, and it
was the second common AEs in this study (Table 3). NoGrade 4 acute dermatitis was seen. The differences in AEs
between the two arms were not significant (p > 0.05)
(Table 3). Late AEs were very mild in both arms (Table 4).
Only Grade 1–2 chronic gastrointestinal (GI) and genito-
urinary (GU) toxicities were observed in this study. Grade
2 chronic GI toxicity was seen in 2 patients in arm A and
1 in arm B, while Grade 2 chronic GU toxicity was only
seen in 1 patient in arm A (Table 4). All patients were suc-
cessfully managed conservatively or symptomatically, and
were symptom-free at last follow-up.
Discussion
It was previously reported that based on the Surveillance,
Epidemiology, and End Results (SEER) database, the rate
of brachytherapy use for cervical cancer in the United
States fell from 83% in 1988 to 43% in 2003, and one of
the most important reasons was increased utilization of
highly conformal radiation therapy techniques such as
IMRT [14]. The recommended dose to the vaginal cuff for
postoperative high risk cervical cancer patients is 12 Gy in
2 fractions of high dose rate (HDR) brachytherapy follow-
ing 50.4 Gy of EBRT. This is much lower than the dose
recommended for unresected cervical cancer patients [6].
Accordingly, it’s feasible to facilitate the adoption of EBRT
boost to the vaginal cuff as an alternative to brachytherapy
for postoperative cervical cancer. And it is also recom-
mended that an additional 10-15Gy highly conformal
EBRT boost to the vaginal cuff may be considered to re-
place brachytherapy following whole-pelvic EBRT [15].
IMRT has been frequently used for cervical cancer in re-
cent years, and has been demonstrated to be able to pro-
vide a relatively precise dose distribution to the CTV
while reducing the dose to OARs, consequently decreas-
ing complications with possible enhancement or no loss
of curative effect in postoperative cervical cancer patients
Figure 1 Disease-free survival curves for arm A (IMRT/VMAT SIB) and B (IMRT/VMAT followed by LCAB).
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therapy technique available in recent years. Many studies
had reported the encouraging results of this technique in
several kinds of cancers [22-25]. EBRT boost techniques
explored in this study were IMRT/VMAT SIB and LCAB
with 3D-CRT following pelvic IMRT/VMAT. Both tech-
niques can perform the boost to the vaginal cuff. To our
knowledge, this is the first study to report the safety and
efficacy of an EBRT boost to the vaginal cuff, and make a
comparison between two boost techniques in postopera-
tive cervical cancer patients with high risk factors.Figure 2 Overall survival curves for arm A (IMRT/VMAT SIB) and B (IMRT/VMIn this study, the 3-year DFS and OS for the SIB group
were 88.7% and 91.8%, respectively, which were not sig-
nificantly different from those in LCAB group (93.4%,
and 100%), with p = 0.89 and p = 0.21, respectively. Local
failure was only observed in 1 patient in the SIB group,
and was isolated to the vaginal cuff. Our results show
that both the SIB and LCAB techniques can provide ex-
cellent local-regional control, DFS and OS. These results
also compare well with others reported in the literature.
Some previous studies delivered adjuvant radiotherapy
with a conventional radiotherapy technique and withoutAT followed by LCAB).
Table 3 Acute grade 3–4 adverse events (AEs) in arms A
and B occurring during concurrent chemoradiotherapy
AEs Arm A (n = 42) Arm B (n = 38) p value
N (%) N (%)
Grade 3
Leukopenia 9 (21.4) 6 (15.8) 0.42
Neutropenia 5 (11.9) 2 (5.3) 0.29
Thrombocytopenia 1 (2.4) 0 (0) 0.34
GI 4 (9.5) 1 (2.6) 0.20
Dermatitis 8 (19.0) 6 (15.8) 0.70
Grade 4
Leukopenia 2 (4.8) 1 (2.6) 0.62
Neutropenia 1 (2.4) 0 (0) 0.34
GI: gastrointestinal toxicity.
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currence rates and 4–5 year OS of 8.6-21.6% and 71–
96.7%, respectively [3,26-28]. Other studies performed
adjuvant IMRT without a vaginal cuff boost [29], and re-
ported 3- and 5-year DFS and OS of 91.2% and 91.1%,
respectively [29]. Our results compare well with studies
that performed adjuvant pelvic radiotherapy with a vagi-
nal brachytherapy boost [30-32]. Chen et al. performed
adjuvant IMRT (50.4 Gy in 28 fractions) followed by
brachytherapy (6 Gy in 3 insertions); and reported a 3-
year local-regional control, DFS and OS of 93%, 78% and
98%, respectively [30]. Pieterse et al. delivered conven-
tional four-field radiotherapy and brachytherapy to
post-operative, high risk cervical cancer patients [32].
The 5-year cancer-specific survival and DFS in that
study were 86% and 85%.
The extent of hematologic toxicity can be affected by
chemotherapy regimen as well as radiotherapy. When ad-
juvant conventional radiotherapy and concurrent chemo-
therapy were performed, Grade 3–4 leukopenia in 43
(35.2%), granulocytopenia in 35 (28.7%), and thrombo-
cytopenia in 1 (0.8%) patients were reported [3]. SeveralTable 4 Chronic AEs observed in arms A and B
AEs Arm A (n = 42) Arm B (n = 38) p value
N (%) N (%)
Grade 1
GI 2 (4.8) 1 (2.6) 0.62
GU 1 (2.4) 2 (5.3) 0.50
Grade 2
GI 2 (4.8) 1 (2.6) 0.62
GU 1 (2.4) 0 (0) 0.34
Grade 3 0 (0) 0 (0)
Grade 4 0 (0) 0 (0)
GI: gastrointestinal toxicity; GU: genitourinary toxicity.studies demonstrated that hematologic toxicity could be
reduced with IMRT in comparison to conventional radio-
therapy [19,30,31,33,34]. Chen et al. compared the toxicity
of adjuvant IMRT and conventional radiotherapy followed
by brachytherapy with concurrent weekly cisplatin [31].
This study demonstrated that Grade 2 hematologic tox-
icity in the IMRT and conventional radiotherapy groups
were observed in 9 (27%) and 11 (31%) patients, while
Grade 3 hematologic toxicity were noted in 2 (6%) and 3
(9%) patients, respectively. Mell et al. treated cervical
cancer patients with IMRT and concurrent cisplatin, and
observed Grade 3–4 anemia, granulocytopenia and leu-
kopenia in 3 (8.1%), 1 (2.7%), and 4 (10.8%) patients, re-
spectively [35]. There were more Grade 3–4 hematologic
toxicities reported in our study. Leukopenia was the most
common Grade 3–4 acute AE in our study, and was ob-
served in 11 (26.2%) and 7 (17.8%) patients in arms A
and B, respectively (Table 2). There were no significant
differences between the two arms. The adjuvant concur-
rent chemotherapy used in our study was 4 cycles of TP,
BP or FP, which may cause more hematologic toxicity
than weekly cisplatin alone. Similar results were re-
ported by another study, and Grade 3–4 hematological
toxicity was 32.3% when concurrent adjuvant FP chemo-
therapy was administered with IMRT without vaginal
cuff boost [29].
As to the GI and GU toxicities, Chen et al. reported
that IMRT had significant lower acute Grade 1–2 GI
(36% vs. 80%, p = 0.00012), and GU (30% vs. 60%, p =
0.022) toxicities when compared with the conventional
radiation group [27]. Furthermore, they demonstrated
that the IMRT group also resulted in lower rates of
chronic Grade 1–3 GI (6 vs. 34%, p = 0.002), and GU (9
vs. 23%, p = 0.231) toxicities [31]. Similar results were
also reported by other studies [19,30,33,34]. In our
study, we demonstrated that concurrent chemotherapy
with the SIB and LCAB techniques was well tolerated
with low incidences of acute and chronic GI and GU
toxicity (Tables 3 and 4). Our results were similar to
other studies where no boost was performed after pelvic
IMRT. In one such study, Folkert et al. reported that
2.9% acute Grade 3 GI toxicity, and no acute Grade 3 or
higher GU toxicity was observed, and that chronic
Grade 1 GI and GU toxicity occurred in 5 (14.7%) and 4
(11.8%) patients, while chronic Grade 2 GU toxicity oc-
curred in 1(2.9%) patient [29].
The weaknesses of this study are due to its retrospect-
ive and single-institution nature, the small sample size,
and the lack of standardization in the chemotherapy.
Moreover, the difference in the efficacy of an EBRT ver-
sus a brachytherapy boost to the vaginal cuff cannot be
compared directly. However, to our knowledge, this is
the first study to report the safety and efficacy of an
EBRT boost to the vaginal cuff, and make comparison
Wang et al. BMC Cancer  (2015) 15:257 Page 7 of 8between two boost techniques in postoperative high-risk
cervical cancer patients.
Conclusions
In conclusion, the current study suggests that good onco-
logic outcomes are achievable with both IMRT/VMAT
SIB and IMRT/VMAT followed by LCAB to the vaginal
cuff and concurrent chemotherapy for postoperative high
risk cervical cancer patients. Both techniques are safe and
feasible, with good local tumor control, good DFS and OS,
and well tolerated. There were no significant differences
between the two the radiation techniques.
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